Human organic cation transporter 1 (hOCT1) as a mediator of bendamustine uptake and cytotoxicity in chronic lymphocytic leukemia (CLL) cells

Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies

(2013) M. Hallek   BLOOD

Bendamustine plus alemtuzumab is safe and feasible treatment for fludarabine refractory chronic lymphocytic leukaemia (CLL)

(2013) Brian T. Hill et al.   BRITISH JOURNAL OF HAEMATOLOGY

Expression ofSLC22A1variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib

(2013) Elisa Herraez et al.   HEPATOLOGY

Novel agents for chronic lymphocytic leukemia

(2013) Mei Wu et al.   Journal of Hematology & Oncology

Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial

(2013) A Cortelezzi et al.   LEUKEMIA

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

(2013) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacokinetics and Excretion of 14C-Bendamustine in Patients with Relapsed or Refractory Malignancy

(2013) Anne-Charlotte Dubbelman et al.   Drugs in research & development

Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia

(2012) D. Rossi et al.   BLOOD

Bendamustine

(2012) Sheridan M. Hoy   DRUGS

Bendamustine for treatment of chronic lymphocytic leukemia

(2012) Julie Elizabeth Chang et al.   EXPERT OPINION ON PHARMACOTHERAPY

Molecular pathogenesis of chronic lymphocytic leukemia

(2012) Gianluca Gaidano et al.   JOURNAL OF CLINICAL INVESTIGATION

Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group

(2012) Kirsten Fischer et al.   JOURNAL OF CLINICAL ONCOLOGY

No Correlation between the Expression of FXR and Genes Involved in Multidrug Resistance Phenotype of Primary Liver Tumors

(2012) P. Martinez-Becerra et al.   MOLECULAR PHARMACEUTICS

Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group

(2011) Kirsten Fischer et al.   JOURNAL OF CLINICAL ONCOLOGY

Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia

(2011) Xose S. Puente et al.   NATURE

Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia

(2011) Víctor Quesada et al.   NATURE GENETICS

Drug uptake transporters in antiretroviral therapy

(2011) Gerard Minuesa et al.   PHARMACOLOGY & THERAPEUTICS

DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma

(2011) Elke Schaeffeler et al.   Genome Medicine

Optimal Use of Bendamustine in Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphomas, and Multiple Myeloma: Treatment Recommendations From an International Consensus Panel

(2010) Bruce D. Cheson et al.   Clinical Lymphoma Myeloma & Leukemia

International network of cancer genome projects

(2010) Thomas J. Hudson (Chairperson) et al.   NATURE

Drug transporter pharmacogenetics in nucleoside-based therapies

(2010) Ekaitz Errasti-Murugarren et al.   PHARMACOGENOMICS

Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver

(2009) Anne T. Nies et al.   HEPATOLOGY

Phase III Randomized Study of Bendamustine Compared With Chlorambucil in Previously Untreated Patients With Chronic Lymphocytic Leukemia

(2009) Wolfgang U. Knauf et al.   JOURNAL OF CLINICAL ONCOLOGY

Transport of Lamivudine [(-)- -L-2',3'-Dideoxy-3'-thiacytidine] and High-Affinity Interaction of Nucleoside Reverse Transcriptase Inhibitors with Human Organic Cation Transporters 1, 2, and 3

(2009) G. Minuesa et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Treanda approved for chronic lymphocytic leukemia

(2008) K. Traynor   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY